Key result
Shenqi drug-coated balloon matches SeQuent Please for 9-month in-segment late loss in coronary ISR.
Why the study?
The clinical safety, effectiveness, and angiographic efficacy of the novel iopromide-based paclitaxel-coated balloon Shenqi in patients with coronary in-stent restenosis had not been investigated.
RCT (n=216)
1:1
Yes
Answers are grounded in this paper and cite their sources.
May support Shenqi DCB use in ISR; hypothesis-generating and requires larger confirmatory trials.
BACKGROUND: Treatment of coronary in-stent restenosis (ISR) remains challenging in contemporary clinical applications. Drug-coated balloon (DCB) angioplasty offers an effective treatment for ISR. Shenqi is a novel iopromide-based paclitaxel-coated balloon and its clinical safety, effectiveness and angiographic efficacy in patients with ISR have not been investigated. METHODS: A total of 216 subjects with the first occurrence of ISR at 11 investigational sites in China were randomly allocated in a 1:1 fashion to treatment with DCB SeQuent Please or Shenqi. Clinical follow-up was planned at 1, 6, 9 and 12 months, and angiographic follow-up was planned at 9 months. The study was powered for the primary endpoint of 9-month in-segment late loss. RESULTS: At 9-month follow-up, the in-segment late loss was 0.29 ± 0.43 mm with Shenqi versus 0.30 ± 0.46 mm with SeQuent Please, and the one-sided 97.5% upper confidence limit of the difference was 0.14 mm, achieving noninferiority of Shenqi compared with SeQuent Please (P = 0.002). In total, 12 patients developed target lesion failure (TLF) in the Shenqi group compared with 16 patients in the SeQuent Please group (10.91% versus 15.09%; P = 0.42) within 1 year. TLF was mainly driven by target lesion revascularization (9.09%) followed by target vessel-related myocardial infarction (1.82%) and cardiovascular death (0.91%) in the Shenqi group. CONCLUSIONS: Shenqi DCB was noninferior to SeQuent Please DCB for the primary endpoint of 9-month in-segment late loss. Shenqi DCB may become an attractive alternative treatment for patients with coronary ISR, withholding the need for additional stent implantation.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) conducted an RCT in coronary in-stent restenosis (n=216). Shenqi paclitaxel-coated balloon vs. SeQuent Please paclitaxel-coated balloon was evaluated on 9-month in-segment late loss (one-sided 97.5% upper confidence limit of the difference 0.14 mm, p=0.002). The Shenqi paclitaxel-coated balloon was noninferior to SeQuent Please for 9-month in-segment late loss in patients with coronary in-stent restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: